Leveraging an RNAi Solution to target Integrins in Scarring and Chronic Fibrosis

• Leveraging self-delivering siRNA technology to silence a novel integrin target that drives the pathological switch to chronic fibrosis
• Unlocking regenerative healing by reversing myofibroblast persistence
• Validating a new treatment paradigm to demonstrate potent target knockdown and functional recovery in models of fibrotic disease

Speakers:

Audrey Bernstein

Cheif Scientific Officer

DUB Therapeutics